Tag: Palisade Stock

The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug.

Today, Palisade Bio (PALI) has announced the successful conclusion of its analysis assessing the impact of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay. PALI-2108, an orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug developed by Palisade, targets patients afflicted with UC.

The obtained data fortifies Palisade Bio’s confidence in the robust anti-inflammatory capabilities of PALI-2108 in managing UC. The superior efficacy of PALI-2108, evidenced by its lower half-maximal inhibitory concentration (IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as an advanced therapeutic option for inflammatory bowel disease patients.

This comprehensive study involved WB samples from 14 clinically healthy adults, comprising five women and nine men. Twelve samples meeting the inclusion criteria were utilized for TNF-α measurement and IC50 value calculation. Donor whole blood underwent treatment with varied concentrations of PALI-2108 and two control compounds known for inhibiting the PDE4 pro-inflammatory pathway, subsequently being challenged with the pro-inflammatory molecule lipopolysaccharide (LPS).

Anti-inflammatory potency was determined by computing IC50 values for TNF-α inhibition. Results from the study showcased the efficacy of PALI-2108 in inhibiting LPS-induced TNF-α production in this ex-vivo peripheral whole blood assay. Pretreatment of human whole blood samples with bioactivated PALI-2108 led to a significant reduction in LPS-induced TNF-α production compared to non-pretreated samples.

The study was conducted in collaboration with Paraza Pharma, Inc., headquartered in Montreal, QC. Palisade Bio’s exceptional operational performance is propelling the clinical advancement of PALI-2108 towards its first-in-human study, slated to commence later this year. Palisade Bio remains dedicated to advancing its innovative research endeavors aimed at enhancing the quality of life for UC patients and those affected by other inflammatory conditions.

Following the release of promising clinical trial data, the shares of Palisade Bio, Inc. (NASDAQ: PALI) are experiencing a notable surge on the US stock charts. As of the last check during current session, PALI stock recorded a remarkable uptick of 105.77%, reaching $8.56.

Palisade Bio (PALI) has disclosed today the successful culmination of its scrutiny evaluating ex-vivo bioactivation of PALI-2108. PALI-2108 is an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in the developmental phase, targeting patients afflicted by UC.

The findings have unveiled that PALI-2108 showcases proficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples, sourced from both healthy volunteers and UC patients. The enzymatic activity in stool samples was gauged through LC-MS analysis, with all samples meeting the target conversion rate within a 24-hour timeframe.

The evaluation has revealed that PALI-2108 was transmutated into its active PDE4 inhibitor form at an average rate of 90.1%, with conversion exhibiting a consistent upward trend over time. This study was conducted in collaboration with Altasciences, headquartered in Montreal, QC. These results fortify Palisade Bio’s confidence in PALI-2108 as a precisely targeted therapy for moderate-to-severe UC.

The successful bioactivation of PALI-2108 into its active PDE4 inhibitor form, maintaining consistently high conversion rates over a 24-hour duration in stool samples, accentuates its potential as an innovative therapeutic intervention for managing UC. Palisade Bio recently participated in IBD Innovate: Product Development for Crohn’s & Colitis, held on April 9-10, 2024, in Cambridge, MA.

As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research collaborator, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio, delivered an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” elucidating on the development of PALI-2108, its distinctive features, competitive positioning, and the clinical trajectory toward late-stage development.

As previously disclosed, the progression of PALI-2108 is backed by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.